Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MBRX

Moleculin Biotech Inc

May 22 • 04:00PM ET

2.39

0.00 0.00 %

Healthcare • Biotechnology • USA • Nano • NASD

May 21, 5:35 PMMoleculin Biotech reports pooled data from 5 Annamycin trials showing no cardiotoxicity even at high cumulative doses

Peers: TNXP APVO IMNN CUE SNTI

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-28.04	Insider Own	0.83%	Shs Outstand	5.34M	Perf Week	13.27%
Market Cap	12.75M	Forward P/E	-	EPS next Y	-3.84	Insider Trans	0.00%	Shs Float	5.29M	Perf Month	-5.91%
Enterprise Value	2.76M	PEG	-	EPS next Q	-1.54	Inst Own	3.21%	Short Float	6.32%	Perf Quarter	2.58%
Income	-32.20M	P/S	-	EPS this Y	82.01%	Inst Trans	1.27%	Short Ratio	2.19	Perf Half Y	-78.18%
Sales	0.00M	P/B	0.84	EPS next Y	24.84%	ROA	-136.70%	Short Interest	0.33M	Perf YTD	-27.79%
Book/sh	2.85	P/C	1.24	EPS next 5Y	49.99%	ROE	-398.45%	52W High	24.20 -90.12%	Perf Year	-89.83%
Cash/sh	1.93	P/FCF	-	EPS past 3/5Y	57.89% 46.71%	ROIC	-197.37%	52W Low	1.79 33.52%	Perf 3Y	-98.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.54% 6.55%	Perf 5Y	-99.82%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	80.65%	Oper. Margin	-	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.38	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.38	EPS Q/Q	79.43%	SMA20	-0.17%	Beta	1.74	Target Price	21.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	0.77%	Rel Volume	1.64	Prev Close	2.39
Employees	17	LT Debt/Eq	0.01	Earnings	May 15 BMO	SMA200	-64.72%	Avg Volume	152.90K	Price	2.39
IPO	Jun 02, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	-51.72% -	Trades		Volume	250,436	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Resumed	H.C. Wainwright	Buy	$4
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform	$14

May-21-26 05:02PM	Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin (GlobeNewswire)
May-15-26 08:30AM	Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial (GlobeNewswire)
May-13-26 08:00AM	Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks (GlobeNewswire) -8.55%
May-12-26 09:30AM	Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits (GlobeNewswire)
May-08-26 08:45AM	Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin (GlobeNewswire)
08:25AM	Loading…
Apr-23-26 08:25AM	Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 (GlobeNewswire)
Apr-21-26 08:36AM	Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-07-26 08:36AM	Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire)
Mar-23-26 08:31AM	Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout (GlobeNewswire)
Mar-19-26 08:36AM	Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 (GlobeNewswire)
Mar-17-26 09:05AM	Moleculin to Present at 38th Annual ROTH Conference (GlobeNewswire) +5.37%
Mar-11-26 09:00AM	Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study (GlobeNewswire)
Feb-19-26 08:39AM	Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds (GlobeNewswire) -44.28%
Feb-18-26 08:20AM	Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) (GlobeNewswire) +5.48%
08:35AM	Loading…
Feb-17-26 08:35AM	Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin (GlobeNewswire) +5.07%
Feb-13-26 08:32AM	Moleculin Launches CEO Corner Platform to Share Strategic Insights (GlobeNewswire)
Feb-05-26 09:15AM	Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire) -6.46%
Jan-13-26 08:55AM	Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects (GlobeNewswire) +5.93%
Jan-12-26 08:36AM	Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs (GlobeNewswire)
Dec-17-25 08:31AM	Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors (GlobeNewswire) -11.73%
Dec-10-25 08:30AM	Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds (GlobeNewswire) -27.15%
Dec-09-25 08:07AM	Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026 (GlobeNewswire) -8.55%
Dec-08-25 08:21AM	Moleculin Announces New Annamycin Collaboration in Brain Tumors (GlobeNewswire)
Nov-26-25 09:15AM	Moleculin to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -22.03%
09:00AM	Moleculin Announces Reverse Stock Split (GlobeNewswire)
Nov-13-25 08:36AM	Moleculin Reports 60% of First 45 Subjects in Pivotal "MIRACLE" Phase 3 AML Trial Consented (GlobeNewswire) -6.91%
Nov-12-25 08:37AM	Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill (GlobeNewswire)
Oct-30-25 08:40AM	Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting (GlobeNewswire) -5.80%
Oct-29-25 08:35AM	Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin (GlobeNewswire)
08:00AM	Loading…
Oct-23-25 08:00AM	Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer (GlobeNewswire) +9.81%
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Sep-26-25 08:45AM	Moleculin Biotech announces issuance of Canadian patent covering Annamycin (TipRanks) +11.87%
Sep-25-25 08:35AM	Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin (GlobeNewswire)
Sep-17-25 12:00PM	Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know (Zacks) +5.18%
Sep-09-25 08:45AM	Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial (GlobeNewswire)
Sep-08-25 08:30AM	Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Aug-28-25 08:30AM	Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds (GlobeNewswire) -35.27%
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +11.33%
08:45AM	Moleculin Issues New Positive AML Overall Survival Data: (GlobeNewswire)
Aug-14-25 09:15AM	Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Aug-13-25 08:05AM	Moleculin Reports Second Quarter 2025 Financial Results and Highlights (GlobeNewswire)
Aug-06-25 08:40AM	Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment (GlobeNewswire)
Jul-30-25 08:35AM	Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin (GlobeNewswire)
Jul-22-25 08:45AM	Moleculin Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-17-25 08:25AM	Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships (GlobeNewswire) +30.56%
Jul-09-25 08:35AM	Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans (GlobeNewswire) +9.70%
Jun-21-25 09:25AM	Moleculin Biotech prices 16.08M shares at 37c in public offering (TipRanks)
Jun-20-25 09:20AM	Moleculin Announces $5.9 Million Public Offering (GlobeNewswire) -54.20%
Jun-18-25 07:45AM	Moleculin Participates in Virtual Investor "What This Means" Segment (GlobeNewswire) -12.46%
07:30AM	Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML (GlobeNewswire)
Jun-12-25 09:20AM	Moleculin Biotech announces What This Means virtual investor segment (TipRanks)
Jun-11-25 09:15AM	Moleculin Participates in Virtual Investor "What This Means" Segment (GlobeNewswire)
Jun-05-25 08:00AM	Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) (GlobeNewswire)
Jun-04-25 08:45AM	Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) (GlobeNewswire) -19.83%
May-15-25 03:12AM	Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -8.17%
May-14-25 07:30AM	Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
May-13-25 05:19AM	EMA approves Moleculins application for Phase IIb/III AML trial (Clinical Trials Arena)
May-12-25 08:40AM	Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial (GlobeNewswire)
May-07-25 09:00AM	Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast (GlobeNewswire)
May-06-25 09:00AM	Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin (GlobeNewswire)
May-05-25 08:45AM	Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents (GlobeNewswire)
Apr-29-25 08:35AM	Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer (GlobeNewswire)
Apr-17-25 08:30AM	Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-02-25 08:41AM	Moleculin Biotech doses first patient in Phase 3 MIRACLE trial (TipRanks)
05:51AM	Moleculin Biotech begins dosing subjects in combination therapy trial for AML (Clinical Trials Arena)
Apr-01-25 09:55AM	Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:30AM	Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy (Zacks) -6.96%
Mar-25-25 03:00AM	Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com) +8.49%
01:38AM	Q4 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-24-25 10:50AM	Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:05AM	Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-25 08:05AM	Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast (GlobeNewswire)
Mar-11-25 08:45AM	Moleculin Biotech, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (PR Newswire)
Mar-10-25 08:45AM	Moleculin to Present at the 37th Annual ROTH Conference (PR Newswire)
Mar-06-25 08:30AM	Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity (PR Newswire) -5.17%
Mar-03-25 08:30AM	Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium (PR Newswire) -10.85%
Feb-25-25 12:35PM	Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) +20.56%
Feb-13-25 01:19PM	Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? (Benzinga) +202.38%
01:05PM	Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds (PR Newswire)
09:25AM	Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Feb-12-25 10:25AM	Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine (Clinical Trials Arena) -17.24%
Feb-11-25 08:40AM	Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial (PR Newswire) -27.91%
Jan-27-25 08:30AM	Moleculin Participates in Virtual Investor 'What This Means' Segment (PR Newswire)
Jan-08-25 08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 and 2026 (PR Newswire)
08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 (PR Newswire)
Dec-11-24 08:00AM	Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model (PR Newswire) +14.72%
Nov-18-24 08:15AM	New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML (PR Newswire) -7.01%
Nov-14-24 08:15AM	Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 (PR Newswire) +23.11%
Nov-12-24 10:59PM	Moleculin Biotech Reports Financial Highlights and Future Plans (TipRanks) +5.18%
08:00AM	Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Nov-11-24 11:19PM	Q3 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-24 09:00AM	Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast (PR Newswire)
Nov-04-24 08:30AM	Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Oct-18-24 08:57AM	Moleculin Biotech Highlights Annamycins AML Treatment Potential (TipRanks) +9.53%
Oct-17-24 08:40AM	Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available (PR Newswire)
Oct-09-24 05:02PM	Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... (GuruFocus.com)

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Co-FounderMr. Walter V. Klemp

Executive VP & CFOMr. Jonathan P. Foster CPA

Chief Scientific OfficerDr. Donald H. Picker Ph.D.

Co-FounderDr. Waldemar Priebe Ph.D.

Sc.D.Dr. John Paul Waymack M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foster Jonathan P.	Chief Financial Officer	Jun 23 '25	Buy	0.37	270,270	100,000	287,587	Jun 23 04:35 PM
KLEMP WALTER V	CEO and President	Jun 23 '25	Buy	0.37	675,675	250,000	743,607	Jun 23 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBRX

Moleculin Biotech Inc

Upgrade your Finviz experience